Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 20/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 9/20 | 0.65 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.53 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.53 |
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.53 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.53 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.53 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.53 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL832819 | 1.00 | HDAC1 (0.71) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL831783 | 0.93 | HDAC1 (0.71) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL831784 | 0.93 | HDAC1 (0.71) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833123 | 0.92 | HDAC1 (0.80) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833122 | 0.92 | HDAC1 (0.80) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833750 | 0.91 | HDAC1 (0.78) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833751 | 0.91 | HDAC1 (0.78) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833208 | 0.89 | HDAC1 (0.71) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL833209 | 0.89 | HDAC1 (0.71) | HDAC1HDAC8HDAC3HDAC2HDAC6 | |
| SCHEMBL832895 | 0.89 | HDAC1 (0.70) | HDAC1HDAC8HDAC3HDAC2HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | claimed |
| EP-2131840-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*Bio Pte Ltd (SG) | 2009-12-16 | — | — | EP | claimed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | claimed |
| WO-2008108741-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S*BIO PTE LTD (SG) | 2008-09-12 | — | — | WO | claimed |
| US-20210100775-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2021-04-08 | — | — | US | disclosed |
| EP-2131840-B1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | MEI PHARMA INC (US) | 2018-10-17 | — | — | EP | disclosed |
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| US-20150258068-A1 | COMBINATION THERAPIES | MEI PHARMA, INC. | 2015-09-17 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| US-8143282-B2 | Heterocyclic compounds | S*BIO PTE LTD. (SG) | 2012-03-27 | — | — | US | disclosed |
| EP-1937650-B1 | HETEROCYCLIC COMPOUNDS | S BIO PTE LTD (SG) | 2011-06-15 | — | — | EP | disclosed |
| US-20100247543-A1 | TREATMENT AND PREVENTION OF NEURODEGENERATIVE DISEASES | ORYZON GENOMICS, S.A. (ES) | 2010-09-30 | — | — | US | disclosed |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | S'BIO PTE LTD (SG) | 2010-04-22 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| US-20090048300-A1 | Heterocyclic Compounds | S*BIO PTE LTD. (SG) | 2009-02-19 | — | — | US | disclosed |
| EP-1937650-A1 | HETEROCYCLIC COMPOUNDS | S*Bio Pte Ltd (SG) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007030080-A1 | HETEROCYCLIC COMPOUNDS | S*BIO PTE LTD (SG) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090048300-A1 | Heterocyclic Compounds | HDAC1, HDAC3, HDAC11 | HDAC1 1/4885HDAC8 4/4885HDAC3 2/4885 |
| US-20100098691-A1 | COMBINATION OF BENZIMIDAZOLE ANTI-CANCER AGENT AND A SECOND ANTI-CANCER AGENT | PAICS, HDAC5, HDAC4 | HDAC1 47/4885HDAC8 7/4885HDAC3 29/4885 |
| US-20210100775-A1 | COMBINATION THERAPIES | DDIT3, MCL1, ERCC2 | HDAC1 25/4885HDAC8 22/4885HDAC3 34/4885 |
| US-20150258068-A1 | COMBINATION THERAPIES | HDAC1, HDAC8, HDAC5 | HDAC1 1/4885HDAC8 2/4885HDAC3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.